Table 1.
Clinicopathologic and prognostic features of the 66 stage II small bowel adenocarcinomas
| N of cases (%) | N of deaths (%) | HR (95% CI), P value (Cox) | |
|---|---|---|---|
| Age at SBA diagnosis | |||
| > 62 years | 33 (50) | 12 (36) | 2.89 (0.93–8.99), P = 0.050 |
| < 62 years | 33 (50) | 4 (12) | 1 |
| Sex | |||
| Male | 42 (64) | 11 (26) | 1.87 (0.64–5.45), P = 0.237 |
| Female | 24 (36) | 5 (21) | 1 |
| Site | |||
| Duodenum | 5 (8) | 2 (40) | 2.07 (0.47–9.17), P = 0.381 |
| Jejunum/ileum | 61 (92) | 14 (23) | 1 |
| Predisposing condition | P = 0.056 | ||
| Crohn’s disease | 20 (30) | 6 (30) | 6.91 (0.83–57.45), P = 0.074 |
| Lynch syndromea | 7 (11) | 2 (29) | 6.25 (0.57–68.98), P = 0.135 |
| None (sporadic) | 18 (27) | 7 (39) | 9.34 (1.15–76.04), P = 0.037 |
| Celiac disease | 21 (32) | 1 (5) | 1 |
| Celiac disease | |||
| Yes | 21 (32) | 1 (5) | 0.13 (0.02–0.98), P = 0.008 |
| No | 45 (68) | 15 (33) | 1 |
| T stage | |||
| T4 | 17 (26) | 7 (41) | 2.60 (0.97–7), P = 0.068 |
| T3 | 49 (74) | 9 (18) | 1 |
| R status | |||
| R1 | 6 (9) | 2 (33) | 2.46 (0.55–10.96), P = 0.291 |
| R0 | 60 (91) | 14 (23) | 1 |
| Number of LN examined | |||
| Low | 29 (44) | 10 (34) | 2.03 (0.73–5.63), P = 0.166 |
| Adequate | 37 (56) | 6 (16) | 1 |
| High-risk features, any | |||
| Yes | 41 (62) | 14 (34) | 3.73 (0.84–16.57). P = 0.083 |
| No | 25 (38) | 2 (8) | 1 |
| Vascular or perineural invasion | |||
| Yes | 35 (53) | 9 (26) | 1.23 (0.46–3.31), P = 0.681 |
| No | 31 (47) | 7 (23) | 1 |
| Histologic grade | |||
| High (G3) | 23 (35) | 7 (30) | 1.53 (0.57–4.13), P = 0.403 |
| Low (G1–G2) | 43 (65) | 9 (21) | 1 |
| Extended high-risk features | |||
| Yes | 52 (79) | 15 (29) | 3.33 (0.44–25.43), P = 0.166 |
| No | 14 (21) | 1 (7) | 1 |
| Histologic subtype group | |||
| Cohesive (glandular/medullary) | 54 (82) | 9 (17) | 0.23 (0.08–0.61), P = 0.006 |
| Non-cohesive (diffuse/mixed) | 12 (18) | 7 (58) | 1 |
| MMR-d | |||
| Yes | 28 (42) | 3 (11) | 0.25 (0.07–0.87), P = 0.014 |
| No | 38 (58) | 13 (34) | 1 |
CI confidence interval; HR hazard ratio; LN lymph nodes, MMR-d mismatch repair deficiency; SBA small bowel adenocarcinoma
aIncluding 1 genetically confirmed Lynch syndrome patient and 6 cases strongly suspected for Lynch syndrome due to their histomolecular profiles